Oncology & Contrast Demand Forecast
$15-25 USD / hour
Posted 1 minute ago
•
Ends in 6 days
$15-25 USD / hour
I need a data-driven forecast that shows how demand for oncology medicines and contrast agents will evolve in a selection of key markets. I will pinpoint the exact countries once we begin, but expect a mix of mature and high-growth regions rather than a global roll-up. What I expect from you • A clear, defensible methodology explaining the data sources, assumptions, and forecasting model you will use (IQVIA, IMS, WHO datasets, national tender data, etc.). • Five-year demand and growth projections for each agreed-upon country, broken down by major therapeutic class (solid tumors, hematology, immuno-oncology) and by contrast agent segment. • Visual outputs—tables and charts in Excel or Power BI—plus a concise executive summary that translates the numbers into actionable insight. • A short slide deck highlighting key growth drivers, headwinds, and any red flags for market entry. Acceptance criteria Your final report needs to match all figures to cited sources, include an editable model, and present country insights that are internally consistent with the regional totals. To be considered, please attach a brief project proposal outlining your data sources, analytical approach, and timeline. I will review these proposals and move quickly to award the project so we can dive straight into the country selection and data gathering phase.
Project ID: 40830161
About the project
10 proposals
Open for bidding
Remote project
Active 9 secs ago
Place your bid
Bid amount Email addressBenefits of bidding on Freelancer
Set your budget and timeframe
It's free to sign up and bid on jobs
10 freelancers are bidding on average $19 USD/hour for this job


Oncology and contrast agent demand forecasting requires reconciling fragmented data sources across regulatory environments, pricing structures, and market maturity levels—a common friction point that derails forecast credibility. This proposal anchors to IQVIA, IMS Health, and WHO datasets with country-specific tender data to build defensible five-year projections by therapeutic class and contrast segment. Methodology isolates three analytical layers: epidemiological demand drivers (incidence, treatment adoption), supply-side constraints (manufacturing capacity, regulatory approvals), and macro factors (pricing pressure, reimbursement policy shifts). Solid tumors, hematology, and immuno-oncology each receive distinct growth curves based on historical penetration patterns in comparable markets. Statistical modeling uses SPSS or R to validate assumption sensitivity and flag outlier risk. Deliverables include an editable Excel model with transparent assumption cells, Power BI dashboards showing country-level breakdowns and regional reconciliation, and an executive summary translating figures into market entry risk assessment. A focused slide deck isolates growth drivers and market headwinds for board-level communication. Timeline: Data sourcing and methodology finalization in week one, model build and validation in weeks two-three, final deliverables and revisions by week four. Full audit trail of source citations included.


Greetings, with 12 years of experience, around 475 completed projects, and as a Top 1% Verified Freelancer, I can develop a structured, data-driven five-year demand forecast for oncology medicines and contrast agents across your selected markets. Here’s how I’ll help: - Gather and validate data from WHO, IQVIA/IMS, national health authorities, tender records, and other credible market sources, subject to access. - Build country-level forecasts by solid tumors, hematology, immuno-oncology, and contrast agent segments. - Apply transparent assumptions covering market growth, disease burden, treatment adoption, pricing, and healthcare access. - Create an editable Excel forecasting model with charts, tables, and source references. - Deliver an executive summary and concise slide deck covering growth drivers, market risks, and entry opportunities. I’ll reconcile country projections with regional totals and clearly distinguish sourced figures from estimates and assumptions. Could you share the likely number of countries and whether you already have access to IQVIA data, or should I build the methodology around publicly available sources?


I can build a defensible five-year demand forecast for oncology medicines and contrast agents across the selected markets, with clear splits by therapeutic class and contrast segment. I’ll turn the country-level results into an editable model, concise executive summary, and a short slide deck that highlights growth drivers, headwinds, and market-entry risks. I will start by validating the most reliable source mix for each market, using IQVIA/IMS where available, plus WHO, national tender, and public health datasets to triangulate demand and keep figures consistent. From there I’ll define the assumptions, model the trends, check internal consistency against regional totals, and refine the tables, charts, and narrative so the final report is cited, readable, and decision-ready. What countries should I prioritize first? Best, Sonia


I got you! I can build a defensible five-year oncology medicines and contrast agents demand forecast for your selected mature and high-growth markets, with cited sources, editable Excel/Power BI outputs, and an executive slide summary. My brief proposal: I’ll use IQVIA/IMS where available, WHO/GLOBOCAN incidence data, national tender/procurement data, reimbursement lists, import/sales proxies, guideline adoption, pricing/access assumptions, and CAGR/scenario modeling by therapy class and contrast segment. Timeline: methodology/data map in 2–3 days, first country model/demo in 5–7 days, full report and deck after country scope confirmation. I’m young, a fast learner, detail-focused, and available 24/7. Get the demo first before you pay. Two quick questions: Which countries are highest priority, and do you want forecasts in volume units, value, or both? Let’s chat and discuss the answers so I can start immediately. Kind regards, Haroon Z


I can build a defensible five-year demand forecast for oncology medicines and contrast agents across the agreed countries, with separate views for solid tumors, hematology, immuno-oncology, and contrast segments. I can also provide a clear methodology, source map, and a concise executive summary that turns the numbers into practical market-entry insight for your selected markets. I will use a research-based forecasting model grounded in IQVIA/IMS, WHO data, national tender sources, and other cited market evidence, with assumptions clearly stated and country outputs kept internally consistent with regional totals. Deliverables will include an editable Excel model, tables and charts, and a short slide deck; if you already have preferred countries or source constraints, I can align the structure to those from the start. Hira Yousuf


I can build a defensible five-year demand forecast for oncology medicines and contrast agents in your selected markets. My approach combines IQVIA, WHO, and national tender data with transparent assumptions, forecasting by country, therapeutic class (solid tumors, hematology, immuno-oncology), and contrast agent segment. You'll receive an editable Excel or Power BI model, an executive summary, and a short deck on growth drivers, headwinds, and entry risks, with every figure cited.


I can develop a transparent five-year demand forecast for oncology medicines and contrast agents, tailored to the selected countries rather than relying on broad global averages. I’ll begin by defining market scope, product segments, units and historical baselines. The analysis will draw on available sources such as IQVIA/IMS data, WHO datasets, national health statistics, tender records and published market research, with every source and assumption documented. I’ll build an editable Excel forecasting model using historical trends, market growth drivers, treatment adoption, demographic factors and scenario analysis. Outputs will include country-level projections for solid tumors, hematology, immuno-oncology and contrast-agent segments, with regional totals reconciled against country estimates. I’ll also prepare clear charts, an executive summary and a concise slide deck covering growth opportunities, risks and market-entry considerations. A practical timeline is scope and data assessment first, followed by modelling, validation and final reporting; timing will depend on the number of countries and availability of licensed datasets.
内容来自 Freelancer News,版权归原作者所有。
阅读原文 ↗